Redhill Biophrma ADR (RDHL)

$1.20 +0.03 (2.56%)
Market Cap 5.41M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 41,500
Avg Vol 2,325,040
Day's Range N/A - N/A
Shares Out 4.54M
Stochastic %K 79%
Beta 4.83
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
Shortsalwayswin
Shortsalwayswin Dec. 4 at 1:11 PM
$RDHL back down to $1
0 · Reply
cryptoish
cryptoish Dec. 4 at 4:35 AM
$RDHL scam-sarel
0 · Reply
Michl2000
Michl2000 Dec. 2 at 5:48 PM
$RDHL 10M from court case are 2,5* market cap 🤔🐒
0 · Reply
Genesys01
Genesys01 Dec. 2 at 4:04 PM
$RDHL Regaining compliance in RH understanding means: "Traffic sign is green for more dilution". Israel Scam.
0 · Reply
cryptoish
cryptoish Dec. 1 at 8:46 PM
$RDHL
0 · Reply
JISVI
JISVI Dec. 1 at 12:08 PM
$RDHL https://www.prnewswire.com/news-releases/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement-302629014.html
0 · Reply
Balmus
Balmus Dec. 1 at 12:03 PM
$RDHL RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement https://www.prnewswire.com/news-releases/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement-302629014.html
0 · Reply
DARKP00L
DARKP00L Nov. 28 at 5:56 PM
$RDHL this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 28 at 5:44 PM
🎯 Target Hit 🏁 📨 From Nov 12, 2025 💊 $RDHL 💵 Entry: $1.0300 ✅ Ext: $1.1900 💰 P/L: +15.53% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Genesys01
Genesys01 Nov. 28 at 3:19 PM
$RDHL The prospectus from 26th of November means a dilution of 10%. Means the dilution-neutral stock value should be at 0.963 based on todays price of 1.07.
0 · Reply
Latest News on RDHL
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Dec 1, 2025, 7:00 AM EST - 4 days ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Nov 4, 2025, 9:30 AM EST - 4 weeks ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 22, 2025, 4:50 PM EDT - 6 weeks ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 6 weeks ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Oct 6, 2025, 8:00 AM EDT - 2 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 29, 2025, 7:00 AM EDT - 2 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Sep 5, 2025, 7:00 AM EDT - 3 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 3 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 3 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 4 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 5 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 7 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 7 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 7 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 8 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 8 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 8 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 9 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 9 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 10 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 10 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 10 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 11 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 11, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

GILD

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Feb 20, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AMGN GILD

Shortsalwayswin
Shortsalwayswin Dec. 4 at 1:11 PM
$RDHL back down to $1
0 · Reply
cryptoish
cryptoish Dec. 4 at 4:35 AM
$RDHL scam-sarel
0 · Reply
Michl2000
Michl2000 Dec. 2 at 5:48 PM
$RDHL 10M from court case are 2,5* market cap 🤔🐒
0 · Reply
Genesys01
Genesys01 Dec. 2 at 4:04 PM
$RDHL Regaining compliance in RH understanding means: "Traffic sign is green for more dilution". Israel Scam.
0 · Reply
cryptoish
cryptoish Dec. 1 at 8:46 PM
$RDHL
0 · Reply
JISVI
JISVI Dec. 1 at 12:08 PM
$RDHL https://www.prnewswire.com/news-releases/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement-302629014.html
0 · Reply
Balmus
Balmus Dec. 1 at 12:03 PM
$RDHL RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement https://www.prnewswire.com/news-releases/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement-302629014.html
0 · Reply
DARKP00L
DARKP00L Nov. 28 at 5:56 PM
$RDHL this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 28 at 5:44 PM
🎯 Target Hit 🏁 📨 From Nov 12, 2025 💊 $RDHL 💵 Entry: $1.0300 ✅ Ext: $1.1900 💰 P/L: +15.53% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Genesys01
Genesys01 Nov. 28 at 3:19 PM
$RDHL The prospectus from 26th of November means a dilution of 10%. Means the dilution-neutral stock value should be at 0.963 based on todays price of 1.07.
0 · Reply
JISVI
JISVI Nov. 27 at 10:48 AM
$RDHL https://za.investing.com/news/sec-filings/redhill-biopharma-increases-maximum-amount-for-atthemarket-ads-offering-93CH-4003929
1 · Reply
scared_money_problems
scared_money_problems Nov. 25 at 10:44 PM
$RDHL tmrw 💹🚀
2 · Reply
JISVI
JISVI Nov. 22 at 8:51 AM
$RDHL https://stockstotrade.com/news/redhill-biopharma-ltd-rdhl-news-2025_11_05/
0 · Reply
Azlvr
Azlvr Nov. 21 at 7:32 PM
$RDHL 😕 https://www.trustpilot.com/review/www.jccapitalconsultants.com
0 · Reply
Mattcriger
Mattcriger Nov. 20 at 6:33 PM
$RDHL definitely being manipulated to stay over $1 but not much past that 😆
0 · Reply
indigo10
indigo10 Nov. 19 at 12:38 AM
$RDHL will soon be a $10 stock, if there is a reverse split .. 🤣
0 · Reply
Stockking24
Stockking24 Nov. 18 at 4:14 PM
$RDHL is today the day it gos below $1 will see once it does it will drop hard and no site of return RS soon..
0 · Reply
newbulloh2
newbulloh2 Nov. 14 at 9:34 PM
$DFLI + $RDHL same 1.12 value!!
0 · Reply
newbulloh2
newbulloh2 Nov. 14 at 9:31 PM
$MSPR $RDHL 1.12 value!!!
0 · Reply
Roger73PF
Roger73PF Nov. 12 at 6:30 PM
$RDHL this stock is strongly undervalued, manipulated... but just my opinion
2 · Reply
DonZulu
DonZulu Nov. 12 at 6:01 PM
$RDHL 6-10$ stock watch in january
1 · Reply
1004yo
1004yo Nov. 11 at 11:03 PM
$RDHL Most of the volume is OTC. Could you explain what this means?
1 · Reply